GlassScriptPhysician profile
Jacob C Lasalle
NPI 1669883484
$4,546.71
in general payments reported to CMS, 2019-2025
33 companies · $722 in 2025
The $722 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,785 · 2020: $319 · 2021: $350 · 2022: $481 · 2023: $478 · 2024: $411 · 2025: $722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,611.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,611.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $1,054.91 | 2019-2022 | |
| Abbvie INC. | $528.99 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $502.01 | 2019-2025 | Relistor |
| Bioventus LLC | $334.84 | 2019-2025 | Durolane, Gelsyn-3, Xcell |
| Globus Medical, INC. | $193.50 | 2025 | Senza |
| Medtronic USA, INC. | $191.16 | 2019 | |
| Boston Scientific Corporation | $174.84 | 2019-2021 | |
| Medtronic, INC. | $163.71 | 2022-2023 | Intellis Adaptivestim |
| Alexion Pharmaceuticals, INC. | $157.97 | 2019-2021 | |
| Lundbeck LLC | $150.41 | 2020-2024 | Vyepti |
| Catalyst Pharmaceuticals, INC. | $129.78 | 2020-2022 | |
| Ipsen Biopharmaceuticals, INC | $101.43 | 2024-2025 | Dysport |
| Allergan, INC. | $92.37 | 2020-2021 | |
| Forte Bio-Pharma LLC | $76.88 | 2022-2025 | Prolate, Nalocet, Tanlor |
| Depuy Synthes Sales INC. | $66.26 | 2019-2025 | Orthovisc, Monovisc |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $64.05 | 2024 | |
| Redhill Biopharma INC. | $62.20 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $56.97 | 2022 | |
| Merz Pharmaceuticals, LLC | $45.55 | 2025 | Xeomin |
| Scilex Pharmaceuticals INC. | $45.04 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $42.54 | 2019 | |
| Valinor Pharma, LLC | $38.06 | 2025 | Movantik |
| Abbott Laboratories | $37.95 | 2021 | |
| Collegium Pharmaceutical, INC. | $35.64 | 2020-2025 | Xtampza |
| Amgen INC. | $33.21 | 2019 | |
| Mdd US Operations, LLC | $30.70 | 2019 | |
| Almatica Pharma LLC | $22.63 | 2021 | |
| Horizon Therapeutics Plc | $21.58 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $21.52 | 2020 | |
| Vertos Medical, INC. | $19.62 | 2022 | |
| Pfizer INC. | $18.62 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $16.85 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.92 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Lasalle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.